Your browser doesn't support javascript.
loading
Cross-protection to new drifted influenza A(H3) viruses and prevalence of protective antibodies to seasonal influenza, during 2014 in Portugal.
Guiomar, Raquel; Pereira da Silva, Susana; Conde, Patrícia; Cristóvão, Paula; Maia, Ana Carina; Pechirra, Pedro; Rodrigues, Ana Paula; Nunes, Baltazar; Milho, Luís; Coelho, Ana Paula; Fernandes, Aida; Caseiro, Paula; Rodrigues, Fernando; Correia, Lurdes; Pereira-Vaz, João; Almeida, Sofia; Branquinho, Paula; Côrte-Real, Rita; Viseu, Regina; Peres, Maria João; Sanches, Raquel; Dantas, Filipa; Freitas, Ludovina; Andrade, Graça; Maurílio, Manuel; Caldeira, Filomena; Cabral Veloso, Rita; Mota-Vieira, Luisa; Soares, Marta; Couto, Ana Rita; Bruges-Armas, Jácome; Pinto, Rita Mouro; Sobrinho Simões, Joana; Costa, Maria do Rosário; Guimarães, João Tiago; Martins, Luís; Cunha, Mário.
Afiliação
  • Guiomar R; Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P., Portugal. Electronic address: raquel.guiomar@insa.min-saude.pt.
  • Pereira da Silva S; Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P., Portugal. Electronic address: susana.pereira@insa.min-saude.pt.
  • Conde P; Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P., Portugal. Electronic address: patricia.conde@insa.min-saude.pt.
  • Cristóvão P; Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P., Portugal. Electronic address: paula.cristovao@insa.min-saude.pt.
  • Maia AC; Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P., Portugal. Electronic address: carinamaia04@gmail.com.
  • Pechirra P; Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P., Portugal. Electronic address: pedro.pechirra@insa.min-saude.pt.
  • Rodrigues AP; Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P., Portugal. Electronic address: ana.rodrigues@insa.min-saude.pt.
  • Nunes B; Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P., Portugal. Electronic address: baltazar.nunes@insa.min-saude.pt.
  • Milho L; Administração Regional de Saúde do Algarve, I.P., Laboratório Regional de Saúde Pública Laura Ayres, Portugal. Electronic address: lmilho@arsalgarve.min-saude.pt.
  • Coelho AP; Administração Regional de Saúde do Algarve, I.P., Laboratório Regional de Saúde Pública Laura Ayres, Portugal. Electronic address: acoelho@arsalgarve.min-saude.pt.
  • Fernandes A; Administração Regional de Saúde do Algarve, I.P., Laboratório Regional de Saúde Pública Laura Ayres, Portugal. Electronic address: afernandes@arsalgarve.min-saude.pt.
  • Caseiro P; Centro Hospitalar de Coimbra, E.P.E., Portugal.
  • Rodrigues F; Centro Hospitalar de Coimbra, E.P.E., Portugal. Electronic address: imuno@huc.min-saude.pt.
  • Correia L; Centro Hospitalar de Coimbra, E.P.E., Portugal. Electronic address: lurdescorreia@chc.min-saude.pt.
  • Pereira-Vaz J; Centro Hospitalar de Coimbra, E.P.E., Portugal. Electronic address: joaovaz@huc.min-saude.pt.
  • Almeida S; Centro Hospitalar da Cova da Beira, E.P.E., Portugal. Electronic address: s.sofia.almeida@gmail.com.
  • Branquinho P; Centro Hospitalar de Lisboa Central, E.P.E., Portugal. Electronic address: biomolecular@sapo.pt.
  • Côrte-Real R; Centro Hospitalar de Lisboa Central, E.P.E., Portugal. Electronic address: rita.cortereal@chlc.min-saude.pt.
  • Viseu R; Centro Hospitalar Setúbal, E.P.E., Portugal.
  • Peres MJ; Centro Hospitalar Setúbal, E.P.E., Portugal. Electronic address: mjmperes@gmail.com.
  • Sanches R; Hospital Central do Funchal, E.P.E., Portugal.
  • Dantas F; Hospital Central do Funchal, E.P.E., Portugal.
  • Freitas L; Hospital Central do Funchal, E.P.E., Portugal.
  • Andrade G; Hospital Central do Funchal, E.P.E., Portugal. Electronic address: drgraca@sesaram.pt.
  • Maurílio M; Hospital do Espírito Santo, E.P.E., Évora, Portugal. Electronic address: mmaurilio@hevora.min-saude.pt.
  • Caldeira F; Hospital do Espírito Santo, E.P.E., Évora, Portugal. Electronic address: filomenacaldeira1@gmail.com.
  • Cabral Veloso R; Hospital do Divino Espírito Santo de Ponta Delgada, E.P.E., Portugal. Electronic address: Rita.TR.Veloso@azores.gov.pt.
  • Mota-Vieira L; Hospital do Divino Espírito Santo de Ponta Delgada, E.P.E., Portugal. Electronic address: Luisa.MQ.Vieira@azores.gov.pt.
  • Soares M; Hospital do Santo Espírito de Angra do Heroísmo, E.P.E. and Institute for Molecular and Cell Biology (IBMC), University of Porto, Portugal.
  • Couto AR; Hospital do Santo Espírito de Angra do Heroísmo, E.P.E. and Institute for Molecular and Cell Biology (IBMC), University of Porto, Portugal. Electronic address: arcouto@seebmo.org.
  • Bruges-Armas J; Hospital do Santo Espírito de Angra do Heroísmo, E.P.E. and Institute for Molecular and Cell Biology (IBMC), University of Porto, Portugal. Electronic address: jacome@seebmo.org.
  • Pinto RM; Hospital de São João, E.P.E., Portugal. Electronic address: rita_m_p@hotmail.com.
  • Sobrinho Simões J; Hospital de São João, E.P.E., Portugal. Electronic address: jssimoes@hsjoao.min-saude.pt.
  • Costa MDR; Hospital de São João, E.P.E., Portugal. Electronic address: mrsscosta@gmail.com.
  • Guimarães JT; Hospital de São João, E.P.E., Portugal. Electronic address: jtguimar@med.up.pt.
  • Martins L; Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P.E., Portugal. Electronic address: lmartins@ipolisboa.min-saude.pt.
  • Cunha M; Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P.E., Portugal. Electronic address: mcunha@ipolisboa.min-saude.pt.
Vaccine ; 35(16): 2092-2099, 2017 04 11.
Article em En | MEDLINE | ID: mdl-28318771
ABSTRACT

INTRODUCTION:

Immune profile for influenza viruses is highly changeable over time. Serological studies can assess the prevalence of influenza, estimate the risk of infection, highlight asymptomatic infection rate and can also provide data on vaccine coverage. The aims of the study were to evaluate pre-existing cross-protection against influenza A(H3) drift viruses and to assess influenza immunity in the Portuguese population. MATERIALS AND

METHODS:

We developed a cross-sectional study based on a convenience sample of 626 sera collected during June 2014, covering all age groups, both gender and all administrative health regions of Portugal. Sera antibody titers for seasonal and new A(H3) drift influenza virus were evaluated by hemagglutination inhibition assay (HI). Seroprevalence to each seasonal influenza vaccine strain virus and to the new A(H3) drift circulating strain was estimated by age group, gender and region and compared with seasonal influenza-like illness (ILI) incidence rates before and after the study period.

RESULTS:

Our findings suggest that seroprevalences of influenza A(H3) (39.9%; 95% CI 36.2-43.8) and A(H1)pdm09 (29.7%; 95% CI 26.3-33.4) antibodies were higher than for influenza B, in line with high ILI incidence rates for A(H3) followed by A(H1)pdm09, during 2013/2014 season. Low pre-existing cross-protection against new A(H3) drift viruses were observed in A(H3) seropositive individuals (46%). Both against influenza A(H1)pdm09 and A(H3) seroprotection was highest in younger than 14-years old. Protective antibodies against influenza B were highest in those older than 65years old, especially for B/Yamagata lineage, 33.3% (95% CI 25.7-41.9). Women showed a high seroprevalence to influenza, although without statistical significance, when compared to men. A significant decreasing trend in seroprotection from north to south regions of Portugal mainland was observed.

CONCLUSIONS:

Our results emphasize that low seroprotection increases the risk of influenza infection in the following winter season. Seroepidemiological studies can inform policy makers on the need for vaccination and additional preventive measures.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus da Influenza A / Influenza Humana / Proteção Cruzada / Anticorpos Antivirais Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vírus da Influenza A / Influenza Humana / Proteção Cruzada / Anticorpos Antivirais Idioma: En Ano de publicação: 2017 Tipo de documento: Article